Merck & Company Inc (MRK)vsSanofi ADR (SNY)
MRK
Merck & Company Inc
$120.79
-1.36%
HEALTHCARE · Cap: $283.78B
SNY
Sanofi ADR
$44.38
+4.74%
HEALTHCARE · Cap: $104.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 39% more annual revenue ($65.77B vs $47.35B). SNY leads profitability with a 16.0% profit margin vs 13.6%. SNY appears more attractively valued with a PEG of 3.81. SNY earns a higher WallStSmart Score of 51/100 (C-).
MRK
Hold50
out of 100
Grade: D+
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-42.4%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+5.5%
Fair Value
$49.78
Current Price
$44.38
$5.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SNY
The primary concerns for SNY are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while SNY is a mature play — different risk/reward profiles.
SNY carries more volatility with a beta of 0.28 — expect wider price swings.
SNY is growing revenue faster at 6.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SNY scores higher overall (51/100 vs 50/100), backed by strong 16.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?